Drugs / CBM588
CBM588
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05759741 | Jan 2023 → Jul 2024 | rectal cancer | Huashan Hospital | Unknown | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06399419 | Jun 2024 → Oct 2026 expected | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | Osel, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05122546 | Nov 2021 → Jan 2027 expected | clear cell renal carcinoma, papillary renal cell carcinoma, sarcomatoid renal cell carcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03829111 | May 2019 → Dec 2023 | clear cell renal carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03922035 | Apr 2019 → Feb 2027 expected | hematopoietic and lymphoid cell neoplasm | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07037004 | Jan 2027 → Oct 2028 expected | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT01077245 | Feb 2010 → Nov 2013 | Clostridium difficile colitis | Osel, Inc. | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07383441 | Jun 2026 → Jan 2033 expected | clear cell renal carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05724511 | Feb → Jun 2023 | cardiovascular disorder, depressive disorder | China Medical University Hospital | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBM588 | “This study is a Phase 2 blinded, placebo-controlled, randomized clinical trial of an oral probiotic product, MIYA-BM Fine Granules \[Clostridium butyricum MIYAIRI 588 Strain...” NCT01077245 ↗3“CBM588 is a strain of bacteria that can restore species of Bifidobacterium to the microbiome.” NCT05122546 ↗ “CBM588” NCT03922035 ↗ |
| Known as | C. butyricum CBM 588 Probiotic Strain | “C. butyricum CBM 588 Probiotic Strain” NCT03922035 ↗ |
| Known as | C. butyricum MIYAIRI 588 | “The investigators provide probiotics (C. butyricum MIYAIRI 588) to intervention group and provide nothing to the control group.” NCT05724511 ↗ |
| Known as | Clostridium butyricum CBM 588 Probiotic Strain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03922035 ↗ |
| Known as | Clostridium butyricum CBM588 Strain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07037004 ↗ |
| Known as | Clostridium butyricum MIYAIRI 588 Strain | “This study is a Phase 2 blinded, placebo-controlled, randomized clinical trial of an oral probiotic product, MIYA-BM Fine Granules \[Clostridium butyricum MIYAIRI 588 Strain...” NCT01077245 ↗ |
| Known as | MIYA-BM | “This study is a Phase 2 blinded, placebo-controlled, randomized clinical trial of an oral probiotic product, MIYA-BM Fine Granules \[Clostridium butyricum MIYAIRI 588 Strain...” NCT01077245 ↗ |
| Known as | MIYAIRI 588 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05724511 ↗ |
| Known as | MO-03 | “To compare investigator assessed progression-free survival of participants with advanced clear cell renal cell carcinoma (ccRCC) randomized to standard of care immunotherapy...” NCT07383441 ↗ |
| Modality | Other / unclassified | “This study is a Phase 2 blinded, placebo-controlled, randomized clinical trial of an oral probiotic product, MIYA-BM Fine Granules \[Clostridium butyricum MIYAIRI 588 Strain...” NCT01077245 ↗ |
| Route | Oral | “Two hundred patients who meet all eligibility criteria will be randomized in a 1:1 fashion to receive either MIYA-BM (2g/dose) or placebo orally twice daily for 42 days.” NCT01077245 ↗ |